2.86

4.68% -0.13

Lexeo Therapeutics Inc (LXEO)

Overview News Price History Financials Discussions Forecast

Lexeo Therapeutics Inc stock is traded at $2.86, with a volume of 206.89K. It is down -4.68% in the last 24 hours and down -49.82% over the past month. Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

Previous Close:

$2.99

Open:

24h Volume:

206.89K

Relative Volume:

0.81

Market Cap:

$98.90M

Revenue:

Net Income/Loss:

$-86.60M

P/E Ratio:

-1.0097

EPS:

-2.8324

Net Cash Flow:

$-67.37M

1W Performance:

-26.74%

1M Performance:

-49.82%

6M Performance:

-75.07%

1Y Performance:

-81.14%

1-Day Range:

$2.825

$3.3838

1-Week Range:

$2.825

$3.91

52-Week Range:

$2.825

$19.50

Lexeo Therapeutics Inc Stock (LXEO) Company Profile

Name

Lexeo Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

(212) 547-9879

Address

345 PARK AVENUE SOUTH, NEW YORK

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LXEO's Discussions on Twitter

Compare LXEO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXEO Lexeo Therapeutics Inc	2.84	98.90M	0	-86.60M	-67.37M	-2.8324
VRTX Vertex Pharmaceuticals Inc	476.00	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	696.16	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	615.92	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	241.67	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	268.23	29.71B	3.32B	-860.46M	-1.04B	-8.32

Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-13-24	Initiated	Robert W. Baird	Outperform
Jun-06-24	Initiated	H.C. Wainwright	Buy
Nov-28-23	Initiated	Chardan Capital Markets	Buy
Nov-28-23	Initiated	JP Morgan	Overweight
Nov-28-23	Initiated	Leerink Partners	Outperform
Nov-28-23	Initiated	RBC Capital Mkts	Outperform
Nov-28-23	Initiated	Stifel	Buy

View All

Lexeo Therapeutics Inc Stock (LXEO) Latest News

Feb 27, 2025

Lexeo stock hits 52-week low at $4.23 amid market challenges - MSN

Feb 27, 2025

Feb 25, 2025

Lexeo stock plunges to 52-week low at $3.42 amid market challenges By Investing.com - Investing.com South Africa

Feb 25, 2025

Lexeo stock plunges to 52-week low at $3.42 amid market challenges - Investing.com India

Feb 25, 2025

Feb 22, 2025

Lexeo Therapeutics CEO sells $19,090 in stock By Investing.com - Investing.com Nigeria

Feb 22, 2025

Lexeo Therapeutics chief medical officer sells $10,410 in stock By Investing.com - Investing.com Canada

Feb 22, 2025

Feb 21, 2025

SG Americas Securities LLC Makes New $72,000 Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Feb 14, 2025

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Price Target from Brokerages - MarketBeat

Feb 14, 2025

Feb 11, 2025

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of “Buy” from Brokerages - Defense World

Feb 11, 2025

Feb 10, 2025

Market Recap: Lexeo Therapeutics Inc (LXEO)’s Negative Momentum, Closing at 4.95 - The Dwinnex

Feb 10, 2025

Feb 07, 2025